Improved Progression-Free Survival in Multiple Myeloma Patients Following Three-Drug Therapy with Autologous Stem Cell Transplant
Dana-Farber Cancer InstitutePatients with multiple myeloma who have been treated with a three-drug combination therapy have a growing number of choices for subsequent treatment. Results of a new study led by researchers at Dana-Farber Cancer Institute can help patients and their physicians weigh benefits and risks of each option.